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Abstract: Background: Patients’ non-adherence to immunosuppressant treatment after organ transplantation may lead to 
organ failure, graft loss and death. Non-adherence among Swedish kidney transplant recipients has not previously been 
studied. Hence the aim of this study was to explore non-adherence among Swedish kidney transplant recipients by using 
self-report instruments as well as testing the hypothesis that there is a difference in self-reported symptoms, beliefs about 
medicine and social support between respondents with or without self reported non-adherence. 
Materials and Methodology: In the present cross sectional study 250 renal transplant recipients participated by replying to 
a questionnaire. Two validated instruments were included, one on beliefs about medicine (the BMQ©), the other on non-
adherence (the BAASIS©). 
Results: Only 46 % never failed to follow the medical treatment with respect to taking the drugs, dosage or timing (>2 hrs 
from prescribed time). Timing was the most frequently reported deviation (48 %). Forty-seven patients (16 %) had failed 
taking at least one dose of the prescribed immunosuppressants during the past four weeks. Four individuals had reduced 
the prescribed doses. Only one reported taking a ‘drug holiday’. Nine participants reported stronger concerns than 
necessities for immunosuppressive medication. For the BMQ the necessity scores were extremely high while the scores 
for concern were low. Risk behaviour identified by the BAASIS had no association in risk attitudes as identified in the 
BMQ. The only factor relating to non-adherence was lack of social support (p=0.022). 
Conclusion: In general adherence was high. Identification of the exceptions remains a challenge. 
Keywords: The BAASIS, the BMQ, immunosuppression, kidney transplant, life-long treatment, non-adherence, self-report 
instruments. 
INTRODUCTION 
  Every day, transplant nurses establish numerous clinical 
encounters with organ transplant recipients (TxR), where one 
vital aspect is to empower the patient to cope with the 
lifelong immunosuppressive medication and its possible side 
effects. Since lack of empowerment and too many side 
effects might lead to non-adherence, the nurse’s target is to 
view the patient as a person in a process of learning and to 
understand the perspective of the TxR in order to prevent 
non-adherence and its consequences. Until now, non-
adherence in Swedish kidney transplant patients has not 
previously been studied. There was a need to establish a 
knowledge base about this complex phenomenon in relation 
to TxR, in order to improve the everyday clinical meetings 
between the TxR and the transplant staff. Therefore, the 
starting point in this study was aimed at exploring non-
adherence among Swedish kidney transplant recipients by 
the use of self-report instruments that also explored attitudes  
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toward medication. We also wished to test the hypothesis 
that there is a difference in self-reported symptoms, beliefs 
about medication and social support between respondents 
with or without self reported non-adherence. 
  Patients’ lack of adherence in various medical contexts 
has been carefully studied. However, a 1996 review 
concluded that there were few usable results for clinical use 
[1]. Adherence to long-term therapies has been defined as 
”the extent to which a person’s behaviour – taking 
medication, following a diet, and/or executing lifestyle 
changes, corresponds with agreed recommendations from a 
health care provider” [2, p.17]. Despite this definition, health 
care professionals still act within a paradigm built on power, 
mastery and control [3] and we know from previous studies 
that only about half the patients with various chronic 
conditions requiring long-term therapies actually take their 
prescribed medication [2]. One such condition is being an 
organ transplant recipient, a state involving lifelong 
medication. From a nursing professional point of view, graft 
rejection is one of the most alarming consequences, which in 
worst case may lead to graft loss. It is well known that non-
adherence to the immunosuppressive treatment after organ 
transplantation is associated with a poor outcome [4-6]. Dew 
et al., showed in a meta analysis of 147 studies that the rate 42    The Open Nursing Journal, 2012, Volume 6  Lennerling and Forsberg 
of non-adherence in transplant recipients regarding 
immunosuppressive treatment, diet, exercise, and other 
healthcare requirements was 19 to 25 cases per 100 persons 
per year. Non-adherence to the immunosuppressive drugs 
was highest in kidney transplant recipients (36 cases per 100 
persons per year) [7]. In a review article by Butler et al., on 
adherence to medication after renal transplantation, a median 
of 22 % of the recipients (range, 18-26 %) were considered 
to be non-adherent. It was also stated that a median of 36 % 
of the graft losses were associated with non-adherence 
(range, 14-65 %). There was a sevenfold increased risk of 
graft failure in the non-adherent patients compared with the 
adherent [4]. 
  Several studies show that strict adherence to 
immunosuppressive drugs regarding taking, dosing and 
timing is required. For transplant recipients, even minor 
variations from the prescribed immunosuppressive therapy 
have been shown to be associated with an increased risk for 
poor outcome such as late acute rejections, poor function and 
graft loss [8-12]. In a prospective study with five years 
follow-up post kidney transplantation, 23 % were identified 
as non-adherent, 21 % of those experienced late acute 
rejection versus 8 % of the adherent recipients [10]. 
  A key problem is that it is difficult to discover non-
adherence behaviour. Several methods such as blood-assays, 
pill count and prescription refill have been used, but no 
method is considered the gold standard clinically. 
Demographics, social support, and perceived health have 
proved little correlation with non-adherence [7], but it has 
been suggested that the attitude to medication and related 
beliefs are important factors for adherence to medical 
treatment [13]. We have therefore included that aspect in this 
study. The gold standard of measuring adherence is the use 
of electronic pill count, something that is unrealistic and 
unpractical to be used clinically. Even if the pills are counted 
there is no guarantee that they are actually taken. Various 
self-report instruments have been developed for the purpose 
of examining non-adherence and are described in a recent 
review article by Dobbels et al., [14]. It has been suggested 
that together with clinical judgement and blood-assays, self-
report instruments can be key components for assessment of 
adherence in clinical practice [15]. Thus the aim of this study 
was to explore non-adherence among Swedish kidney 
transplant recipients by using self-report instruments as well 
as testing the hypothesis that there is a difference in self-
reported symptoms, beliefs about medicine and social 
support between respondents with or without self reported 
non-adherence. 
MATERIALS AND METHODOLOGY 
Participants 
  Sweden has over nine million inhabitants and 
Gothenburg is the second largest city in Sweden with the 
largest transplant centre in Scandinavia. Approximately 350 
kidney transplantations are performed yearly in Sweden and 
close to half of them at Sahlgrenska University Hospital in 
Gothenburg. A registry of kidney transplant patients in 
Gothenburg was used to identify all recipients from January 
2005 through June 2009 with functioning grafts and a 
follow-up time of at least six months. In March 2010, 348 
persons were invited by mail to respond to a questionnaire. 
A reminder was sent to those who had not responded after 
three weeks. In all, 258 questionnaires were received (74 % 
response rate), but as eight responders proved to have lost 
their grafts since last report, the study population comprised 
250 persons. Demographic data and immunosuppressive 
therapy are presented in Table 1. 
Table  1.  Demographic Data Regarding Gender, Age, First 
Transplant, Occupation, Level of Education and 
Immunosuppressive Therapy of the 250 Kidney 
Transplant Responders to the Questionnaire 
 
Males, %  69 
Age, years  
 median,  range   54,  19-77 
    30    19 
 30-59    137 
    60    89 
First kidney transplants, %    86 
Occupation, % 
  employed, partly or full time  44 
  sick-leave, full time    27 
 retired    15 
 unemployed   8 
 students    3 
Education, % 
 basic    27 
 high  school  43 
 university                    29 
Immunosuppressive therapy, % 
 cyclosporine     30 
 tacrolimus      61 
  sirolimus or everolimus   7 
  mycophenolate mofetil or 
 sodium  mycophenolate    88 
 prednisolone     66 
 
Data Collection 
  Data were collected by a questionnaire that included two 
existing instruments - the Basel Assessment of Adherence 
with Immunosuppressive medication Scales (BAASIS) 
[16] for which no validation data have been published and 
the Believes about Medicine Questionnaire (BMQ) 
[13,17,18]. Dobbels et al., concluded in their review article 
that two self-report instruments could be recommended and 
we chose to use one of them in this study i.e. the BAASIS 
[14]. 
  The BAASIS instrument was developed to assess 
adherence to immunosuppressive medication in adult 
transplant patients [16]. The instrument measures patients’ 
taking, skipping, timing (>2 hrs from prescribed time) and 
dose reduction of drugs. The recall period is limited to four 
weeks. The BAASIS comprises four questions with a 6-point 
scale for responses ranging from never (0) to every day (5). 
In addition, overall adherence is scored in percentage on a 
VAS scale ranging from 0 to120. 
  The BAASIS was developed for use in interviews but 
there is also a written questionnaire version [18]. In this 
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theoretical framework that adherence decisions are 
influenced by a cost-benefit assessment. In this evaluation, 
personal beliefs about the necessity of the medication for 
maintaining or improving health are balanced against 
concerns about the potential adverse effects of taking it [13]. 
Agreement to use. 
  The items referring to taking medications in the BAASIS 
have been validated for adherence to anti-retrovirals in 
patients with HIV [19]. The validity of the items referring to 
taking and skipping medications for patients with HIV have 
been supported by Deschamps et al., [20]. Permission to use 
the BAASIS in this study was granted by Professor Sabina 
De Geest at the University of Basel in Basel, Switzerland. 
  The Beliefs about Medicine Questionnaire (BMQ) was 
published by Horne et al., in 1999 [13,17]. The BMQ was 
built on the theoretical framework that adherence decisions 
are influenced by a cost-benefit assessment. In this 
evaluation, personal beliefs about the necessity of the 
medication for maintaining or improving health are balanced 
against concerns about the potential adverse effects of taking 
it [13]. Agreement to use the BMQ has been obtained from 
Professor Rob Horne, University of London, UK (by 
Astellas Pharma Ltd Copenhagen). This instrument has been 
used and validated in the context of various chronic 
conditions requiring long-term medication. Respondents are 
requested to score (1 – 5) the extent to which they disagree 
or agree to certain statements, from strongly disagree (1) to 
strongly agree (5). There are two parts in this instrument, one 
general and one specific. The general part contains 8 
statements that can be divided into two subgroups regarding 
overuse, and harm of medication. The item correlation in the 
first subgroup, general harm, ranged from 0.81-0.47; and in 
the second subgroup, general overuse, it ranged from 0.71-
0.51. In the specific part, 10 statements were divided into 
concerns and necessities regarding the drug treatment for the 
disease in question, in this case immunosuppressives. The 
item correlation in the subgroup concerns ranged from 0.80-
0.39; and in the subgroup necessity it ranged from 0.81-0.65. 
The Cronbach’s alpha values for the BMQ scales measured 
for various chronic diseases varied from 0.83-0.47. The test-
retest reliability was considered to be within acceptable 
limits with correlations from 0.60-0.78 [17]. No additional 
factor analysis was performed in this study. 
  For the purpose of the study, two author-constructed 
questions were added. The first question was How do the 
following sentences agree with your daily life as a kidney 
transplant recipient? This was followed by nine statements 
to which responses could range from I completely agree to I 
do not agree at all, all in analogue with the BMQ statements. 
The second question was How do the following sentences 
agree with your experienced situation? followed by 15 
statements such as: “I have to cancel social activities often 
due to my condition,” “My quality of life is very good,” and 
“I often feel lonely.” These statements covered the extent to 
which patients experienced trust in the health care system, 
insight in the treatment, quality of life, and social support. In 
addition, respondents were asked to select, from lists, their 
actual immunosuppressive medication and their perceived 
symptoms and side effects. 
  The statistical analyses were carried out in SPSS version 
19. The Mann-Whitney rank test was used to evaluate 
differences between the two unpaired groups regarding age, 
number of side effects and scores for various beliefs and 
quality of life in respondents with or without self reported 
non-adherence. 
  The study was approved by the Regional Ethical Review 
Board in Gothenburg. 
RESULTS 
  According to the BAASIS scoring system, scores of 1-5 
on any of the four items, taking, skipping, timing and dose 
reduction, should be considered as non-adherence. With this 
definition, 46 % (n= 115) of the 250 patients were adherent. 
The most frequent aberration was timing, i.e. taking the 
drugs more than two hours away from the prescribed time. 
Time was cited by 48 % (n=120). Of the 120, one quarter 48 
% (n=30) reported that this happened at least once a week. 
Of the 250 respondents, 36 % (n= 90) failed only in timing, 
while the others failed in more than one of the four aspects 
of non adherence. 
  More serious deviations to the prescribed regimen were 
acknowledged by 17 % (n=44), all but one stating that they 
had omitted a dose of immunosuppressive medication during 
the past four weeks. Of those 44, 86 % (n=38) told that the 
omission had only occurred once, three had done it every 
other week and one once a week. “Drug holiday”, i.e. 
skipping several doses in a row, was acknowledged by only 
one respondent. The last question in the BAASIS concerned 
taking less than the prescribed dose. Four individuals 
admitted having done so, two of them on a regular basis. 
According to the BAASIS instrument definition wherein 
deviation from even one of the items implies nonadherence, 
54 % (n=135) of the respondents were considered to be non-
adherent. 
  In general, to be adherent to immunosuppressive drugs, 
more than 95% of the prescribed doses need to be taken to 
prevent graft rejection. The self-reported percentage of 
prescribed medication that was actually taken in the last four 
weeks was estimated on a scale ranging from 0 – 120 %, to 
cover overmedication. This estimation was built on the 
respondents’ own perception of their medication taking. A 
total of 244 respondents answered this question. Among 
those, 75 % (n=183) marked 100 %, suggesting complete 
adherence. Nine percent (n=23) reported various values 
below 97 %. 
  The results of the BMQ questions are presented in Table 
2. Among the scores for beliefs about medication in general, 
median values tended to be low for overuse and harm, 
whereas those for benefit were very high. For 
immunosuppressive medication specifically, the necessity 
score was extremely high, median 23 of 25, while the 
concern scores were low. As suggested by the BMQ 
constructors, the difference between the necessity and 
concern scores was also calculated. The necessity-concerns 
differential may be thought of as the result of a cost-benefit 
analysis by each patient in which their perceptions of cost 
(concerns) are weighed against their perception of benefit 
(necessity beliefs). If the difference is positive, the patient 
perceives that the benefits of medication outweigh the costs. 
Four percent (n=9) had values of zero or below, indicating 
stronger concern than sense of necessity. 44    The Open Nursing Journal, 2012, Volume 6  Lennerling and Forsberg 
  The frequency of various symptoms and side effects that 
might be related to the immunosuppressive therapy was high 
(Fig. 1). No symptoms or side effects were reported by only 
11 % (n= 19) of the men and 13 % (n= 10) of the women. 
Fatigue was reported by 77 % (n= 192), 74 % (n= 185) had 
tremor, and 72 % (n= 180) weight gain. In general, women 
reported more symptoms than men, in particular insomnia, 
weight gain, changed bodily appearance, joint pain and hair 
loss; while acne and diarrhoea were the only symptoms 
reported more frequently by men. However the differences 
didn’t reach statistical significance. 
  Age or gender did not differ between the adherent and 
non-adherent groups. Neither was there any difference 
between the groups with respect to the BMQ scores for 
overuse or concern or the necessity minus concern variable. 
Furthermore, the number of reported side effects was not 
increased in the non-adherent group. Out of six tested 
variables for quality of life, the extent of support from family 
and friends was more often classified as minor by the non-
adherent patients (p=0.022). 
DISCUSSION 
  Self reported adherence was surprisingly high in this 
population, as shown by the high scores on the beliefs of the 
necessities of the immunosuppressive treatment in the BMQ 
and also on the VAS scale in the BAASIS. Most kidney 
transplant persons taking part in this study appeared well 
informed about their medication and realised how important 
it was for their wellbeing. They were aware that they must 
take the drugs, although they knew that the drugs conferred 
side effects. Knowing this, we suggest that the transplant 
nurse approach the TxR in a non-paternalistic way and, 
instead of suggesting the risk for non-adherence, focus on 
developing educational strategies that TxR patients can use 
to grasp various aspects of the life long immunosuppressive 
therapy. Adopting such an inside perspective is in line with 
the recommendations of several researchers [21-24]. 
  The two hour time difference from the prescribed 
regimen, as a single marker of non-adherence, seems to be 
too rigid and is not supported by sufficient scientific 
evidence. In a publication by De Geest et al., from 1998, 
timing was measured only with one drug, cyclosporine, and 
patients were already classified as major nonadherent. 
Further, the timing was measured with no upper time limit 
[8]. When using this criterion as a single marker, we found 
that too many patients are classified as non-adherent (36%). 
Some deviation in time (i.e. ± 2 hrs) is common behaviour in 
their everyday life. The argument that such strict time limits 
Table 2.  Summary of Results for the General (G) and Specific (S), Sections of the Beliefs About Medicine Questionnaire 
 
Subgroups (G) Overuse   (G) Harm (G) Benefit  (S) Necessity  (S) Concern 
Number  of  responses  241 239 242 247 246 
Max  points  20 20 20 25 25 
Median    10 9 17  23  11 
Range 4-17 4-16 5-20 9-25 5-25 
Fig. (1). The reported frequency of various symptoms and side effects that may be related to the immunosuppressive therapy divided by men 
and women (n=250). 
Fatique
Tremor
WeightGain
Insomnia
BodyImage
Skin
Hirsutism
JointPain
Vision
Gingivitis
Alpecia
Mood
Pain
Gastritis
Acne
None
Diarrhea
Headache
Constipation
Herpes
Thrush
Fever
Fatique
Tremor
WeightGain
Insomnia
BodyImage
Skin
Hirsutism
JointPain
Vision
Gingivitis
Alpecia
Mood
Pain
Gastritis
Acne
None
Diarrhea
Headache
Constipation
Herpes
Thrush
Fever
s
i
d
e
e
f
f
e
c
t
s
s
i
d
e
e
f
f
e
c
t
s
Sum Frequency
Men Women
50,0    40,0    30,0    20,0    10,0   ,0     10,0    20,0    30,0    40,0    50,0Self-Reported Non-Adherence and Beliefs About Medicine After Transplantation  The Open Nursing Journal, 2012, Volume 6    45 
could compensate for underreporting is not clinically 
relevant due to the fact that most organ transplant recipients 
are prescribed double or triple therapy [16]. 
  Based on the other variables from the BAASIS 
instrument, 17 % of the patients in this study could be 
identified as non-adherent. No statistically significant 
relationships were found between BAASIS and the BMQ, 
gender and age. The only factor relating to self reported non-
adherence was a sense of inadequate social support from 
family and friends. The same finding has been reported by 
Vlaminck et al., [10]. This suggests the need for nurses to 
assess the TxR’s support system i.e. family and friends when 
followed up at the Out-patient Clinic and assess the risk for 
non-adherence on a regular basis and in each individual case. 
  In our population, it doesn’t seem to be risk beliefs that 
cause non-adherence behaviour. This result differs from 
previous studies in patients with other chronic conditions e.g. 
asthma, renal failure or oncology patients [13]. In the study 
by Horn & Weinman [13], medication beliefs  were more 
powerful predictors of reported adherence than clinical and 
socio-demographic factors. The authors concluded that many 
patients engage in an implicit cost-benefit analysis in which 
beliefs about the necessity of their medication are weighed 
against concerns about the potential adverse effects of taking 
it and that these beliefs are related to medication adherence. 
The probable explanation for our results is that, in spite of 
their concerns, most patients realised the necessity of 
immunosuppressives for their wellbeing. They did not let 
their concerns influence their actual behaviour. A recent 
study by Nilsson et al., 2010 showed that there was a 
significant difference in the graft-related threat dimension 
(p<.000) between kidney transplant recipients (KTx) and 
those who had received a liver, a heart or a lung [25]. Thus, 
the KTx’s were more threatened by acute graft rejection than 
those transplanted with a liver, heart or lung. This difference 
remained significant even when the gender differences 
between the groups were controlled for. This could relate to 
the poor health related quality of life experienced when 
being on dialysis treatment [26], but it also suggests that 
their adherence to medication is good due to fear of losing 
the graft and being forced to be back on dialysis again. The 
transplant nurse needs to be sensitive to whether patients are 
acting out of fear instead of general contentment with their 
own capacity to master their health situations. 
  In the summary report from a 2008 consensus conference 
on non-adherence, the following definition of non-adherence 
was suggested “Deviation from the prescribed medication 
regimen sufficient to influence adversely the regimen’s 
intended effect” [27]. This is a good definition, but the 
problem remains that there is no method of measuring how 
much immunosuppression is needed for the individual to 
prevent rejection. Some patients are certainly prescribed 
higher doses than they require, presumably causing various 
side-effects. Clinicians strive to develop methods for 
measuring and defining the target for immunosuppression on 
an individual basis. At the same time, nursing professionals 
need to develop a paradigm in which the patient is looked at 
as person within a learning process and attempt to 
understand the patient’s behavior and actions in relation to 
medication. Conrad (1995) performed a today classic study 
about how patients with epilepsy perceive medication and 
argued that the result might be generalised to apply to many 
other patients with chronic conditions demanding regular 
medication [21]. The results showed that persons with an 
illness or disease are self-regulating rather than adherent and 
that a strategy that, from a medical perspective, might be 
viewed on as non-adherent in fact is a way of achieving a 
sense of control over the disease. This is in line with the 
results of a study of perceptions of experiences of graft 
rejection among organ transplant recipients showing that 
they clearly strived to control the uncontrollable [28]. We 
suggest a 3-step person centered approach: listening to the 
patient’s illness narrative, establishing patient participation 
in decision making regarding their treatment and care plan, 
and documenting the patient’s preferences and needs in the 
medical record [29,30]. This approach makes it more likely 
that  barriers to adherence will be revealed. After mutual 
discussions between the patient and the care giver, 
possibilities to overcome the identified barrier can be 
suggested. 
STUDY LIMITATIONS 
  There are several limitations in this study. One might 
argue that the study lacks originality, as there are similar 
research papers with the same or better design. However, a 
similar research was never done in Sweden and from a 
nursing perspective this is a highly relevant matter. The 
design is cross sectional, which limits interpretation of the 
results. A bias may also be that the non-respondents were 
more nonadherent. The self-report questionnaire was the 
only measurement used, but since self-report instruments can 
be a key component for assessment of adherence in clinical 
practice we believe the instrument was appropriate. In 
retrospect, a factor analysis would have been useful. Another 
weakness concerns BAASIS wherein a recall period of 4 
weeks might be too long, leading to less response accuracy. 
We also need to consider the low but possible temptation 
among the respondents to try to meet the researcher’s 
expectations by being a good patient and give the “expected” 
answer. 
  The study population was Swedish, and factors such as 
the health care system and national level of education 
certainly influence adherence. Finally, from a medical 
perspective, the gold standard in adherence research at the 
present time is an electronic pill count. Other methods are 
judged as inferior. Unfortunately this gold standard also 
reflects a paradigm of power, mastery and control that we 
wish to avoid; therefore the pill count was never considered 
as a methodological option. 
CONCLUSION 
  In conclusion, self-reported non-adherence among 
Swedish kidney transplant recipients was low when not 
involving the 2-hour time difference from the prescribed 
regimen. In spite of their concerns, most patients realised the 
necessity of immunosuppressives for their post-transplant 
wellbeing. Despite the overall high frequency of various 
symptoms and side effects that might be related to the 
immunosuppressive therapy, the number of reported side 
effects was not increased in the non-adherent group. Instead, 
the extent of support from family and friends was 
significantly more often classified as minor by the non-
adherent patients, indicating that social support might be a 46    The Open Nursing Journal, 2012, Volume 6  Lennerling and Forsberg 
predictor for non-adherence among kidney transplant 
recipients while symptom burden is not. Further research 
will involve using grounded theory to explore the main 
concerns in relation to social support and adherence among 
organ transplant recipients. 
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